Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q2 FY26 results · Jul–Sep 2025
Aarti Drugs reported revenue from operations of ₹652.79 crore (up 9.1% from Q2 FY25) and net profit of ₹45.16 crore (up 29.2% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 652.79 | 598.33 | +9.1% | 590.51 | +10.5% |
| Other income | 0.09 | 1.48 | −93.9% | 0.31 | −71.0% |
| Total income | 652.88 | 599.81 | +8.8% | 590.82 | +10.5% |
| Profit before tax | 60.41 | 45.88 | +31.7% | 51.11 | +18.2% |
| Net profit for the period | 45.16 | 34.96 | +29.2% | 53.97 | −16.3% |
| Attributable to shareholders of the company | 45.28 | 35.01 | +29.3% | 53.91 | −16.0% |
| EPS, basic (₹) | 4.95 | 3.83 | +29.2% | 5.91 | −16.2% |
| Net margin (%) | 6.9 | 5.8 | 9.1 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 578.95 | 543.09 | +6.6% | 520.96 | +11.1% |
| Other income | 0.15 | 0.38 | −60.5% | 0.38 | −60.5% |
| Total income | 579.10 | 543.47 | +6.6% | 521.34 | +11.1% |
| Profit before tax | 55.78 | 40.89 | +36.4% | 45.25 | +23.3% |
| Net profit for the period | 41.78 | 30.39 | +37.5% | 48.64 | −14.1% |
| EPS, basic (₹) | 4.58 | 3.33 | +37.5% | 5.33 | −14.1% |
| Net margin (%) | 7.2 | 5.6 | 9.3 |
Consolidated
- Filed with BSE
- 07 Nov 2025, 20:16 IST
- Board meeting
- 07 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Nov 2025, 20:16 IST
- Board meeting
- 07 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Audited
- Source
- XBRL filing on BSE